BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 2465042)

  • 1. B-cell restricted saporin immunotoxins: activity against B-cell lines and chronic lymphocytic leukemia cells.
    Bregni M; Siena S; Formosa A; Lappi DA; Martineau D; Malavasi F; Dorken B; Bonadonna G; Gianni AM
    Blood; 1989 Feb; 73(3):753-62. PubMed ID: 2465042
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of ricin A chain-containing immunotoxins directed against CD19 and CD22 antigens on normal and malignant human B-cells as potential reagents for in vivo therapy.
    Ghetie MA; May RD; Till M; Uhr JW; Ghetie V; Knowles PP; Relf M; Brown A; Wallace PM; Janossy G
    Cancer Res; 1988 May; 48(9):2610-7. PubMed ID: 2451562
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of immunotoxins containing single-chain ribosome-inactivating proteins and an anti-CD22 monoclonal antibody (OM124): in vitro and in vivo studies.
    Bolognesi A; Tazzari PL; Olivieri F; Polito L; Lemoli R; Terenzi A; Pasqualucci L; Falini B; Stirpe F
    Br J Haematol; 1998 Apr; 101(1):179-88. PubMed ID: 9576199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Delivery of saporin to human B-cell lymphoma using bispecific antibody: targeting via CD22 but not CD19, CD37, or immunoglobulin results in efficient killing.
    Bonardi MA; French RR; Amlot P; Gromo G; Modena D; Glennie MJ
    Cancer Res; 1993 Jul; 53(13):3015-21. PubMed ID: 7686448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotoxin-mediated inhibition of chronic lymphocytic leukemia cell proliferation in humans.
    Siena S; Bregni M; Formosa A; Brando B; Marenco P; Lappi DA; Bonadonna G; Gianni AM
    Cancer Res; 1989 Jun; 49(12):3328-32. PubMed ID: 2785850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic therapy with 3BIT, a triple combination cocktail of anti-CD19, -CD22, and -CD38-saporin immunotoxins, is curative of human B-cell lymphoma in severe combined immunodeficient mice.
    Flavell DJ; Noss A; Pulford KA; Ling N; Flavell SU
    Cancer Res; 1997 Nov; 57(21):4824-9. PubMed ID: 9354445
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Delivery of the ribosome-inactivating protein, gelonin, to lymphoma cells via CD22 and CD38 using bispecific antibodies.
    French RR; Penney CA; Browning AC; Stirpe F; George AJ; Glennie MJ
    Br J Cancer; 1995 May; 71(5):986-94. PubMed ID: 7734325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Initial experience in treating human lymphoma with a combination of bispecific antibody and saporin.
    Bonardi MA; Bell A; French RR; Gromo G; Hamblin T; Modena D; Tutt AL; Glennie MJ
    Int J Cancer Suppl; 1992; 7():73-7. PubMed ID: 1428411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response of B-cell lymphoma to a combination of bispecific antibodies and saporin.
    French RR; Bell AJ; Hamblin TJ; Tutt AL; Glennie MJ
    Leuk Res; 1996 Jul; 20(7):607-17. PubMed ID: 8795695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The antitumor activity of an anti-CD22 immunotoxin in SCID mice with disseminated Daudi lymphoma is enhanced by either an anti-CD19 antibody or an anti-CD19 immunotoxin.
    Ghetie MA; Tucker K; Richardson J; Uhr JW; Vitetta ES
    Blood; 1992 Nov; 80(9):2315-20. PubMed ID: 1384801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activity of a monoclonal antibody-saporin-6 conjugate against B-lymphoma cells.
    Bregni M; Lappi DA; Siena S; Formosa A; Villa S; Soria M; Bonadonna G; Gianni AM
    J Natl Cancer Inst; 1988 Jun; 80(7):511-7. PubMed ID: 3259267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of B-cell lymphomas with combination of bispecific antibodies and saporin.
    French RR; Hamblin TJ; Bell AJ; Tutt AL; Glennie MJ
    Lancet; 1995 Jul; 346(8969):223-4. PubMed ID: 7542357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Saporin, a ribosome-inactivating protein used to prepare immunotoxins, induces cell death via apoptosis.
    Bergamaschi G; Perfetti V; Tonon L; Novella A; Lucotti C; Danova M; Glennie MJ; Merlini G; Cazzola M
    Br J Haematol; 1996 Jun; 93(4):789-94. PubMed ID: 8703804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and characterization of an antihuman T-lymphocyte saporin immunotoxin (OKT1-SAP) with in vivo stability into nonhuman primates.
    Siena S; Lappi DA; Bregni M; Formosa A; Villa S; Soria M; Bonadonna G; Gianni AM
    Blood; 1988 Aug; 72(2):756-65. PubMed ID: 3042047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotoxins against CD19 and CD22 are effective in killing precursor-B acute lymphoblastic leukemia cells in vitro.
    Herrera L; Farah RA; Pellegrini VA; Aquino DB; Sandler ES; Buchanan GR; Vitetta ES
    Leukemia; 2000 May; 14(5):853-8. PubMed ID: 10803517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An immunotoxin composed of monoclonal anti-Thy 1.1 antibody and a ribosome-inactivating protein from Saponaria officinalis: potent antitumor effects in vitro and in vivo.
    Thorpe PE; Brown AN; Bremner JA; Foxwell BM; Stirpe F
    J Natl Cancer Inst; 1985 Jul; 75(1):151-9. PubMed ID: 3859688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical studies with the anti-CD19-saporin immunotoxin BU12-SAPORIN for the treatment of human-B-cell tumours.
    Flavell DJ; Flavell SU; Boehm DA; Emery L; Noss A; Ling NR; Richardson PR; Hardie D; Wright DH
    Br J Cancer; 1995 Dec; 72(6):1373-9. PubMed ID: 8519647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of caspase-dependent programmed cell death in B-cell chronic lymphocytic leukemia by anti-CD22 immunotoxins.
    Decker T; Oelsner M; Kreitman RJ; Salvatore G; Wang QC; Pastan I; Peschel C; Licht T
    Blood; 2004 Apr; 103(7):2718-26. PubMed ID: 14525789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapy of human B-cell lymphoma bearing SCID mice is more effective with anti-CD19- and anti-CD38-saporin immunotoxins used in combination than with either immunotoxin used alone.
    Flavell DJ; Boehm DA; Emery L; Noss A; Ramsay A; Flavell SU
    Int J Cancer; 1995 Jul; 62(3):337-44. PubMed ID: 7543082
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the performance of anti-CD7 and anti-CD38 bispecific antibodies and immunotoxins for the delivery of saporin to a human T-cell acute lymphoblastic leukemia cell line.
    Flavell DJ; Cooper S; Okayama K; Emery L; Flavell SU
    Hematol Oncol; 1995; 13(4):185-200. PubMed ID: 7557895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.